TP53 oncogenic variants as prognostic factors in individuals with glioblastoma: a systematic review and meta-analysis

This systematic review and meta-analysis investigated the relationship between somatic oncogenic variants and prognosis, specifically with overall survival (OS) and progression-free survival (PFS) in patients diagnosed with supratentorial glioblastoma. We included longitudinal studies and clinical trials involving a minimum of 40 adult participants diagnosed with supratentorial glioblastoma, wherein the status of variants was assessed. We conducted searches in multiple databases. We assessed bias risk using a modified version of the Quality in Prognosis Studies tool, and the certainty of evidence was evaluated following the principles of the GRADE approach. This study encompassed 23 papers involving 2,555 patients, out of which 716 had reported oncogenic variants. oncogenic variants were associated with a reduced likelihood of 1-year survival (OR 0.52, 95% CI 0.29-0.94). However, our analysis did not reveal any significant impact of variants on overall survival, progression-free survival, or 2-year survival. Therefore, this comprehensive analysis demonstrates that the presence of genetic variants in does not provide useful information for the prognosis of glioblastoma. https://www.crd.york.ac.uk/prospero/, identifier CRD42021289496.